Orphan drug designation provides benefits such as tax credits, PDUFA fee waivers, and 7 years of market exclusivity upon ...
The U.S. Food and Drug Administration has granted orphan drug designation to the investigational therapy MNV-201 for patients with myelodysplastic syndrome, a serious, age-related blood disorder that ...
More than half of patients with high-risk myelodysplastic syndrome may not be receiving guideline-recommended treatment with ...
Venclexta-based regimens showed survival benefits in AML and MDS, with a two-year overall survival rate of 46% and median survival of 18.73 months. Remission was achieved by 57.1% of AML patients and ...
Social worker Marie Brewer talks about the challenges of supporting a loved one with myelodysplastic syndrome (MDS) and ways to find assistance and treatment options. Myelodysplastic syndromes (MDS) ...
ESA treatment in lower-risk MDS patients is linked to improved overall survival and quality of life. Avoiding red blood cell transfusions is associated with significantly better health-related quality ...
Close monitoring via weekly complete blood counts (CBCs) for the first 2 months is essential to mitigate risks, according to Zeidan. Supportive care such as platelet transfusions or growth factors may ...
DelveInsight's " Myelodysplastic Syndrome with Excess Blasts2 Market Insight, Epidemiology And Market Forecast - 2032 " report provides an in-depth understanding of the Myelodysplastic Syndrome with ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...
Track Designation Providing Further Potential Regulatory Advantages as Company Develops First-in-Class Mitochondrial Cell TherapyHAIFA, Israel, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback